October

October 24, 2020

Published by admin_auro at October 24, 2020

Categories

PTC299-based therapy for COVID-19/SARS-COV-2 and other infectious diseases: PTC299, an anti-cancer drug, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of IFN (Interferon)-alpha/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides and decreasing the expression of inflammatory cytokines 24/October/2020, 9.39 am